Vericel (FRA:ATQP) Research & Development: €24.4 Mil (TTM As of Mar. 2026)


FRA:ATQP Vericel Corp FRA:ATQP
75 GF Score
Price €37.00
GF Value €43.45
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Vericel Research & Development?

Vericel FRA:ATQP -1.07% 75 Research & Development is €24.4 Mil as of Mar. 2026. GuruFocus rates FRA:ATQP with a GF Score™ of 75/100 and a GF Value™ of €43.45 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Vericel's Research & Development for the three months ended in Mar. 2026 was €7.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €24.4 Mil.

Vericel  (FRA:ATQP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vericel Research & Development Related Terms

Vericel Research & Development Historical Data

* Premium members only.

The historical data trend for Vericel's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vericel Research & Development Chart

Vericel Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.41 18.83 19.30 23.68 23.54

Vericel Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.72 5.84 5.38 6.19 7.01
FRA:ATQP
75GF Score
Vericel Corp FRA:ATQP
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vericel Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €24.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €24.4 Mil mean?
Vericel (FRA:ATQP) has a Research & Development of €24.4 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Vericel and its competitors.
Is Vericel's Research & Development too high?
Vericel's current Research & Development is €24.4 Mil. Overall, Vericel has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's Research & Development compare to PVLA and TSHA?
Vericel's Research & Development of €24.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vericel and its competitors. Vericel's current Research & Development is €24.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (FRA:ATQP) is currently considered Modestly Undervalued. The stock's GF Value™ is €43.45, compared to a current price of €37.00 — trading 14.8% below its estimated fair value. The current Research & Development is €24.4 Mil. Vericel's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Vericel (FRA:ATQP), the current Research & Development is €24.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vericel (FRA:ATQP) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of €37.00 is trading 14.8% below its estimated GF Value™ of €43.45. GuruFocus considers Vericel to be Modestly Undervalued.

Key valuation signals for FRA:ATQP:

  • Research & Development: €24.4 Mil
  • GF Value™: €43.45 vs. price of €37.00 (14.8% below fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the FRA:ATQP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges VCEL:USA
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
75GF Score

Get the complete analysis for FRA:ATQP

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.00
Price
€43.45
GF Value